The sharp market reaction occurred despite simultaneous positive news from the company regarding Phase 2 results for its FB102 treatment in celiac disease. Following the sell-off, the law firm SueWallSt announced a formal investigation into potential securities law violations. The inquiry focuses on whether argenx provided misleading information to the public concerning the development outlook and the specific progress of the UNITY study.

Investors who purchased argenx stock and suffered losses are now being evaluated for potential recovery claims. According to the firm, eligibility for participation is not contingent on current share ownership; individuals who purchased at allegedly inflated prices and subsequently sold at a loss may also qualify for review. The investigation is being led by Levi & Korsinsky LLP, which represents shareholders in complex litigation matters. Affected parties are encouraged to retain brokerage records and trade confirmations to assess their potential standing.